In contrast to studies in metastatic melanoma [68], we found no enrichment of the canonical Wnt pathway in CD133-positive ES cells compared to CD133-negative cells [69] and the level of CD133 did not predict outcomes. This evidence concerns the gene PROM1 and metastatic melanoma.